Results 101 to 110 of about 648,509 (314)

Methods for Treating Congestive Heart Failure [PDF]

, 2010
The invention features methods of treating or preventing congestive heart failure by administering a polypeptide containing an epidermal growth factor-like domain encoded by a neuregulin ...
Kelly, Ralph, Lorell, Beverly, Marchionni, Mark, Sawyer, Douglas B.   +3 more
core   +2 more sources

Data from Quantitative <i>In Vivo</i> Immunohistochemistry of Epidermal Growth Factor Receptor Using a Receptor Concentration Imaging Approach

, 2023
Kimberley S. Samkoe, Kenneth M. Tichauer, Jason R. Gunn, Wendy A. Wells, Tayyaba Hasan, Brian W. Pogue   +5 more
openalex   +1 more source

Down‐regulation of Shh in the hair follicles of mice during chemotherapy‐induced hair loss is mediated by the JAK/STAT1 signaling pathway

FEBS Open Bio, EarlyView.
We found that during chemotherapy‐induced alopecia (CIA), Sonic hedgehog (Shh) expression significantly decreased in hair follicle Shh+ cells, whereas the Janus‐activated kinase/signal transducer and activator of transcription 1 (JAK/STAT1) signaling pathway was markedly activated.
Ruifang Fan, Jingling Huang, Xiang Lin, Tingjiao Lan, Yuli Tang, Ling Sun, Guixuan Zhou   +6 more
wiley   +1 more source

Feasibility of commercial space manufacturing, production of pharmaceuticals. Volume 1: Executive summary [PDF]

The feasibility of the commercial manufacturing of pharmaceuticals in space is examined. The method of obtaining pharmaceutical company involvement, laboratory results of the separation of serum proteins by the continuous flow electrophoresis process ...

core   +1 more source

Methods for treating congestive heart failure [PDF]

, 2003
The invention features methods of treating or preventing congestive heart failure by administering a polypeptide containing an epidermal growth factor-like domain encoded by a neuregulin ...
Kelly, Ralph, Lorell, Beverly, Marchionni, Mark, Sawyer, Douglas B.   +3 more
core   +1 more source

Epidermal growth factor receptor downregulation by small heterodimeric binding proteins [PDF]

, 2011
No single engineered protein has been shown previously to robustly downregulate epidermal growth factor receptor (EGFR), a validated cancer target.
Ackerman, Amos, Bao, Ben-Kasus, Benjamin J. Hackel, Biscardi, Bonner, Burgess, Chao, Cochran, Countaway, Cunningham, Downward, Ferguson, Forest M. White, French, Friedman, Hackel, Hackel, Herbst, Hoffman, Jason R. Neil, Joslin, K.Dane Wittrup, Kim, Koide, Lee, Li, Messersmith, Morandell, Nicholson, Ogiso, Pedersen, Perera, Pirie, Sharma, Spangler, Tateishi, Winograd-Katz, Wu, Yamauchi, Yarden   +41 more
core   +1 more source

The Antimicrobial Peptide LL-37 Activates Innate Immunity at the Airway Epithelial Surface by Transactivation of the Epidermal Growth Factor Receptor [PDF]

, 2003
G. Sandra Tjabringa, Jamil Aarbiou, Dennis K. Ninaber, Jan W. Drijfhout, Ole E. Sørensen, Niels Borregaard, Klaus F. Rabe, Pieter S. Hiemstra   +7 more
openalex   +1 more source

Supplementary Figure 1 from Epidermal Growth Factor Receptor Variant III Contributes to Cancer Stem Cell Phenotypes in Invasive Breast Carcinoma [PDF]

, 2023
Catherine Del Vecchio Fitz, Kristin C. Jensen, Ryan T. Nitta, A. Hunter Shain, Craig P. Giacomini, Albert J. Wong   +5 more
openalex   +1 more source

Engineering tandem VHHs to target different epitopes to enhance antibody‐dependent cell‐mediated cytotoxicity

FEBS Open Bio, EarlyView.
Tandem VHH targeting distinct EGFR epitopes were engineered into a monovalent bispecific antibody (7D12‐EGA1‐Fc) with more potent ADCC without increasing affinity to EGFR. Structural modeling of 7D12‐EGA1‐Fc showed cross‐linking of separate EGFR domains to enhance CD16a engagement on NK cells.
Yuqiang Xu, Hao Jiang, Limin Chen, Fulai Zhou, Ying Jin, Mark L. Chiu   +5 more
wiley   +1 more source

Effects of EGFR Expression on Anti-tumor Efficacy of Vandetanib or Cediranib Combined with Radiotherapy (RT) in U87 Human Glioblastoma (GBM) Xenografts [PDF]

, 2010
Introduction: Vandetanib is a receptor tyrosine kinase inhibitor (RTKI) with activity against vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR).
Dicker, A. P., Lawrence, Y. R., Liu, Y., Wachsberger, P.   +3 more
core   +2 more sources